A roll-over Study in Patients With Endogenous Cushing's Syndrome
- Conditions
- Cushing's syndrome
- Registration Number
- JPRN-jRCT2080224109
- Lead Sponsor
- Recordati Rare Diseases Japan K.K
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 180
Primary inclusion criteria
- Patients who have completed a Global Novartis-sponsored study receiving osilodrostat.
- Patients who will continue to benefit from treatment with osilodrostat, as judged by the investigator.
- Patient has demonstrated compliance, as assessed by the Investigator, with the parent study protocol requirements.
- Willingness and ability to comply with scheduled visits and treatment plans.
- Written informed consent obtained prior to enrolling into the roll-over study .
Primary exclusion criteria
- Patients who have been permanently discontinued from osilodrostat study treatment in a parent Novartis-sponsor study.
- Patients who are receiving osilodrostat in combination with unapproved or experimental treatments.
- Pregnant or nursing (lactating) women.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method